XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.24.3

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Segment Reporting |
Schedule of financial information by reporting segment | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended | ​
​ | ​ | September 30, | ​ | September 30, | ​
​ | ​ | 2024 | ​ | 2023 | ​ | 2024 | ​ | 2023 | ​
​ | ​ | (in thousands) | ​
Net revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |
Finished pharmaceutical products | ​ | $ | 189,752 | ​ | $ | 176,366 | ​ | $ | 538,755 | ​ | $ | 455,242 | ​
API | ​ |  | 1,462 | ​ | ​ | 4,190 | ​ | ​ | 6,689 | ​ | ​ | 11,048 | ​
Total net revenues | ​ |  | 191,214 | ​ |  | 180,556 | ​ |  | 545,444 | ​ |  | 466,290 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit (loss): | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Finished pharmaceutical products | ​ |  | 105,544 | ​ |  | 109,499 | ​ |  | 302,322 | ​ |  | 262,742 | ​
API | ​ |  | (3,603) | ​ | ​ | (1,096) | ​ | ​ | (15,115) | ​ | ​ | (7,761) | ​
Total gross profit | ​ |  | 101,941 | ​ |  | 108,403 | ​ |  | 287,207 | ​ |  | 254,981 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating expenses | ​ |  | 44,893 | ​ |  | 35,725 | ​ |  | 126,932 | ​ |  | 111,974 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income from operations | ​ |  | 57,048 | ​ |  | 72,678 | ​ |  | 160,275 | ​ |  | 143,007 | ​
Non-operating (expenses) income | ​ |  | (9,365) | ​ |  | (9,041) | ​ |  | (14,473) | ​ |  | (12,993) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income before income taxes | ​ | $ | 47,683 | ​ | $ | 63,637 | ​ | $ | 145,802 | ​ | $ | 130,014 | ​
Schedule of net revenues in the finished pharmaceutical products segment | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended | ​
​ | ​ | September 30, | ​ | September 30, | ​
​ | ​ | 2024 | ​ | 2023 | ​ | 2024 | ​ | 2023 | ​
​ | ​ | (in thousands) | ​
Finished pharmaceutical products segment net revenues: |  | ​ |  |  | ​ |  |  | ​ | ​ |  | ​ | ​ |
BAQSIMI® | ​ | $ | 40,409 | ​ | $ | — | ​ | $ | 85,106 | ​ | $ | — | ​
Glucagon | ​ | ​ | 26,792 | ​ | ​ | 29,514 | ​ | ​ | 82,700 | ​ | ​ | 82,486 | ​
Epinephrine | ​ | ​ | 21,341 | ​ | ​ | 20,199 | ​ | ​ | 75,392 | ​ | ​ | 57,004 | ​
Primatene MIST® | ​ | ​ | 26,055 | ​ | ​ | 24,834 | ​ | ​ | 73,077 | ​ | ​ | 64,837 | ​
Lidocaine | ​ | ​ | 15,884 | ​ | ​ | 15,522 | ​ | ​ | 41,457 | ​ | ​ | 43,174 | ​
Phytonadione | ​ | ​ | 11,721 | ​ | ​ | 7,449 | ​ | ​ | 31,998 | ​ | ​ | 33,017 | ​
Enoxaparin | ​ |  | 5,615 | ​ |  | 7,702 | ​ |  | 17,984 | ​ | ​ | 25,441 | ​
Naloxone | ​ | ​ | 4,037 | ​ | ​ | 4,715 | ​ | ​ | 12,124 | ​ | ​ | 14,774 | ​
Other finished pharmaceutical products | ​ |  | 35,503 | ​ |  | 37,730 | ​ |  | 99,309 | ​ |  | 105,808 | ​
Total finished pharmaceutical products net revenues | ​ | ​ | 187,357 | ​ | ​ | 147,665 | ​ | ​ | 519,147 | ​ | ​ | 426,541 | ​
BAQSIMI® NEB | ​ | ​ | 2,395 | ​ | ​ | 28,701 | ​ | ​ | 19,608 | ​ | ​ | 28,701 | ​
Total finished pharmaceutical products segment net revenues | ​ | $ | 189,752 | ​ | $ | 176,366 | ​ | $ | 538,755 | ​ | $ | 455,242 | ​
Schedule of depreciation and amortization expense by reporting segment | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended | ​
​ | ​ | September 30, | ​ | September 30, | ​
​ | ​ | 2024 | ​ | 2023 | ​ | 2024 | ​ | 2023 | ​
​ | ​ | (in thousands) | ​
Depreciation and amortization expense |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |
Finished pharmaceutical products | ​ | $ | 8,755 | ​ | $ | 8,616 | ​ | $ | 26,086 | ​ | $ | 13,143 | ​
API | ​ |  | 1,038 | ​ |  | 1,003 | ​ |  | 3,045 | ​ | ​ | 2,938 | ​
Total depreciation and amortization expense | ​ | $ | 9,793 | ​ | $ | 9,619 | ​ | $ | 29,131 | ​ | $ | 16,081 | ​
Schedule of net revenues and carrying values of long-lived assets by geographic region | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Net Revenues | ​ | Long-Lived Assets
​ | ​ | Three Months Ended | ​ | Nine Months Ended | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, | ​ | September 30, | ​ | September 30, | ​ | December 31,
​ | ​ | 2024 | ​ | 2023 | ​ | 2024 | ​ | 2023 | ​ | 2024 | ​ | 2023
​ | ​ | (in thousands)
United States(1) |  | $ | 186,514 |  | $ | 178,056 |  | $ | 532,591 |  | $ | 459,909 |  | $ | 187,410 |  | $ | 186,083
China | ​ |  | 178 | ​ | ​ | 833 | ​ | ​ | 2,145 | ​ | ​ | 2,142 | ​ |  | 103,009 | ​ |  | 91,913
France | ​ |  | 4,522 | ​ | ​ | 1,667 | ​ | ​ | 10,708 | ​ | ​ | 4,239 | ​ |  | 37,099 | ​ |  | 37,647
Total | ​ | $ | 191,214 | ​ | $ | 180,556 | ​ | $ | 545,444 | ​ | $ | 466,290 | ​ | $ | 327,518 | ​ | $ | 315,643

X
- Definition Tabular disclosure of depreciation, depletion, and amortization of property and equipment costs. + References No definition available. + Details
Name: | amph_ScheduleOfDepreciationDepletionAndAmortizationTableTextBlock
Namespace Prefix: | amph_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration